Actelion shares led Zurich stocks higher Monday despite the company's admission that its potential blockbuster Opsumit drug failed to meet a key target in late-stage trials.
Rite Aid shares fell in dramatic fashion on Friday.
New bowel drug Trulance will be available for patients later this quarter.
The autoinjector will be free for insured patients and those whose annual income is less than $100,000.
Here's how biotech and healthcare stocks are moving ahead of market's open.
Regulators say company squelched competing drug for infant seizures.
Nominee to oversee health coverage revamp says reform for the individual market should be in place by March